Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Mid Coast Hospital, Southern Maine Health Care, and Central Maine Medical Center have the Best Value Outcomes for Sepsis in Portland, ME


Best Value Outcomes for Sepsis in Portland, ME

“Dexur’s value analysis tracks a patient’s episode of care from the date of admission for 90 days and includes the index hospitalization, rehospitalization, home health, nursing home, and ED costs.”

Dexur’s analysis of medicare claims of hospitals within a 50-mile radius of Portland, ME, showed that Mid Coast Hospital, Southern Maine Health Care, and Central Maine Medical Center had the best value outcomes over a 90-day episode for Sepsis. The episode of care tracks a patient journey from the date of admission for 90 days and includes the index hospitalizations, rehospitalization, home health, nursing home, and ED costs. The total cost of care data helps patients make appropriate choices and helps local ACOs such as MaineHealth Accountable Care Organization to make appropriate referrals choices. The analysis was risk-adjusted, for alive and non-hospice patients and was done at the DRG level, specifically DRG 871: Septicemia Or Severe Sepsis Without MV >96 Hours With Major Complication Or Comorbidity (MCC), to adjust for complications and comorbidities.

Mid Coast Hospital’s total cost of care over a 90 day episode was $22,526 (for the period between July 2016 and June 2019). The index hospitalization cost was $11,652 and the average rehospitalization cost per hospitalization was $5,798. The cost per rehospitalization was at an average of $19,668. Meanwhile, the average ED costs per hospitalization (when ED is involved) was $917.

The average home health cost per hospitalization when a home health agency is involved was $3,592. The average cost per hospitalization for the top home health agency partner for Sepsis for Mid Coast Hospital was:

Southern Maine Health Care’s total cost of care over a 90 day episode was $22,944 (for the period between July 2016 and June 2019). The index hospitalization cost was $11,339 and the average rehospitalization cost per hospitalization was $6,571. The cost per rehospitalization was at an average of $22,852. Meanwhile, the average ED costs per hospitalization (when ED is involved) was $847.

Central Maine Medical Center’s total cost of care over a 90 day episode was $23,263 (for the period between July 2016 and June 2019). The index hospitalization cost was $11,865 and the average rehospitalization cost per hospitalization was $6,460. The cost per rehospitalization was at an average of $20,487. Meanwhile, the average ED costs per hospitalization (when ED is involved) was $1,347.

Share article on social media or email:

Integrating Qualitative Patient Interviews into a Clinical Trial Protocol, Upcoming Webinar Hosted by Xtalks


Xtalks Life Science Webinars

In the era of patient-centred research and healthcare, clinical researchers are being asked to think beyond hypothesis testing, and to engage in sometimes-difficult discussions about the meaningfulness of their trial results.

Join Benoit Arnould, Divisional Principal, Patient Centred Outcomes, ICON plc, Alexia Marrel, Lead Outcomes Researcher, Patient Centred Outcomes, ICON plc and Olga Moshkovich, Lead Outcomes Researcher, Patient Centred Outcomes, ICON plc in a live webinar on Thursday, July 30 at 11am EDT (4pm BST/UK).

In the era of patient-centred research and healthcare, clinical researchers are being asked to think beyond hypothesis testing, and to engage in sometimes-difficult discussions about the meaningfulness of their trial results. Regulators, payers, clinicians and patient advocacy groups all want to understand how innovative products and treatments can change the course of disease, and how patients will experience and value these changes.

The recent draft guidance issued by FDA (Oct 2019) “Patient-Focused Drug Development: Methods to Identify What Is Important to Patients” encourages industry to conduct qualitative research. While most stakeholders recognise the unique value of qualitative research, and researchers have strong qualitative methods to capture and report subjective experience communicated with natural language, adapting and integrating this into sophisticated clinical trials is not always straightforward.

Join this webinar for insights on how to include qualitative research into your trials more effectively. Experts from ICON plc will share knowledge from over five years of successfully designing and conducting entry and exit interviews in clinical trials, and discuss the solid and emerging set of scientific publications available to support this approach.

For more information or to register for this event, visit Integrating Qualitative Patient Interviews into a Clinical Trial Protocol.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

The Orthopaedic Research and Education Foundation, the Scoliosis Research Society and the Pediatric Orthopaedic Society of North America award $240,000 spine grants


Children playing soccer

“The 2020 OREF/SRS/POSNA Transform Practice – Spinal Growth Research Grant program is an exceptional grant with respect to closing critical knowledge gaps in spine deformity in children.”

The Orthopaedic Research and Education Foundation (OREF), the Scoliosis Research Society (SRS) and the Pediatric Orthopaedic Society of North America (POSNA) announced today that research grants of $240,000 have been awarded to Stuart L. Weinstein, MD, of the University of Iowa, Iowa City, Iowa, and Carol A. Wise, PhD, of Texas Scottish Rite Hospital for Children, Dallas. Both investigators received an OREF/SRS/POSNA Transform Practice – Spinal Growth Grant.

Dr. Weinstein’s study, Bracing vs Casting in the Treatment of Idiopathic Early-Onset Scoliosis, seeks to establish the relative short-term effectiveness of casting and bracing in the treatment of idiopathic early-onset scoliosis (IEOS, onset at less than 3 years of age). Despite widespread use, neither of these approaches has been rigorously tested in the IEOS population, leading to the current lack of consensus within the orthopaedic community about the preferred approach.

Dr. Wise’s study, Translating Genomics into Early Onset Scoliosis (EOS) Clinical Care, addresses a condition that encompasses a heterogeneous population representing many underlying genetic etiologies, all with potential for the most severe scoliosis phenotypes when untreated. Perhaps the most frustrating are the so-called idiopathic “infantile” scoliosis (IIS) patients who are severely disfigured but apparently healthy otherwise. This pilot study seeks to discover novel EOS disease genes and uncover new underlying etiologies in this unique patient population.

OREF Research Grants Committee (RGC) chair, Francis Y. Lee, MD, PhD, noted, “The 2020 OREF/SRS/POSNA Transform Practice – Spinal Growth Research Grant program is an exceptional grant with respect to closing critical knowledge gaps in spine deformity in children. It provides significant funding for studies that have been vetted through OREF’s NIH-level peer review process.” Dr. Lee also expressed his gratitude to Brian Snyder, MD, PhD, an NIH-funded clinician-scientist and the OREF Program Director for this grant, stating, “Dr. Snyder did an outstanding job leading the peer-review process and holding a study section review. His contribution to the grant selection process was invaluable and it was an honor to work with him.”

The grant is part of OREF’s Collaborative Research Agenda program, which seeks to bring together stakeholders who share an interest in improving orthopaedic care to identify, prioritize and fund topics that are especially relevant to clinical practice today. “This grant is highly important as the SRS seeks to collaborate and direct research in priority areas. There is nothing more important than improving the treatment of deformity in our youngest patients,” said Paul D. Sponseller, MD, MBA, SRS President.

POSNA President, Michael Vitale, MD, MPH, noted, “The clinical knowledge garnered from these two grants, as well as from the myriad grant applications which could not be funded at this time but which still may come to fruition, will serve to advance the evolution of care in this space. OREF, POSNA and SRS are proud to be able to partner to create this opportunity.”

Funding for the grants was provided by Dr. John and Mrs. Kim Callaghan, SRS, POSNA, Medtronic Inc., DePuy Synthes and Zimmer Biomet.

About the Orthopaedic Research and Education Foundation

The Orthopaedic Research and Education Foundation is a charitable 501(c)(3) organization committed to improving lives by supporting excellence in orthopaedic research. OREF is dedicated to being the leader in supporting research that improves function, eliminates pain, and restores mobility, and is the premier orthopaedic organization funding research across all subspecialties. A list of research and funding priorities is available at https://www.oref.org/grants or by following OREF on Twitter at https://twitter.com/OREFtoday.

About the Scoliosis Research Society

The Scoliosis Research Society is a non-profit, professional organization made up of physicians and allied health personnel. Its primary focus is on providing continuing medical education for health care professionals and on funding/supporting research in spinal deformities. Founded in 1966, SRS has gained recognition as the world’s premier spine deformity society. Please visit http://www.srs.org for further information.

About the Pediatric Orthopaedic Society of North America

The Pediatric Orthopaedic Society of North America (POSNA) is a not-for-profit professional organization of over 1,400 surgeons, physicians, and allied health members passionately dedicated to advancing musculoskeletal care for children and adolescents through education, research, quality, safety and value initiatives, advocacy, and global outreach to children in underserved areas. For more information, visit https://posna.org/.

Share article on social media or email:



Two weeks is how long it took to create an application that could save lives during the COVID-19 pandemic


Can technological innovation be the answer to the crisis caused by COVID-19? Startup Development House proves it is possible. To create a modern solution, limited resources are enough and short delivery time does not have to be a problem at all. The key is agile management.

Innovation in two weeks? It’s possible!

Grace Lake Partners (GLP), a company from Nigeria, asked Startup Development House to create a mobile application to help fight the pandemic. The coronavirus loves when we move around and gather in one place, so this should be avoided. The SocialHealth application helps you arrange a remote doctor’s appointment, make a video call and issue a digital prescription. Less than two weeks have passed since signing the contract and the solution has already been implemented. It’s the first application of this kind in Nigeria.

A serious challenge and flexible approach

How to achieve record-breaking time for design and implementation? Experience in creating IT solutions for startups proves to be priceless. The answer is precisely recognising the client’s needs, rapid prototyping and using the right technologies. Innovation requires us to focus on what is most important for the users, create a prototype and then choose a simple solution. In this case, the design of the application was of secondary matter to the client, while the time of development and wide availability for patients and doctors were crucial.

Speed and availability but also safety

SocialHeath is a Progressive Web App (PWA). This means it is available from your browser, so you don’t have to download it from Google Play or the App Store. The process of registering doctors and patients, specifying the symptoms, planning visits or prescribing medicine has been simplified as much as possible. And what’s essential, the application works properly even with a weak Internet connection. Startup Development House has also taken into account a requirement specific for Nigeria, so the e-prescription includes the doctor’s signature. In two weeks, they have created a solution that is not only user-friendly but also fully secure. All connections and patient data are encrypted. The provider was able to fulfill this requirement basing on previous experience with corporate innovation.

Digital innovation and pandemic

Nigeria is currently facing not only the COVID-19 pandemic but also other infectious diseases. That’s why it is essential that only patients who really have to be there, are in the clinics. The coronavirus forces governments and entrepreneurs to take an innovative approach to problem-solving. Implementing remote work and organising medical ‘televisits’ is a new trend but not the only one. The situation related to the pandemic also has a significant impact on other sectors, such as gastronomy, selling groceries or financial services. Entities that have previously invested in digital transformation are certainly better prepared to face the crisis. For others, it may be crucial to make a quick decision to establish a cooperation with a partner who will develop a new product concept with them, create a prototype and then successfully implement a ready-to-use IT solution.

How to find the right partner?

Matrimonial associations work perfectly here, as we can be involved with an IT partner for a long time (depending on our needs). What’s worth paying attention to?

1. Portfolio. Checking their completed projects and other clients’ opinions is a significant part of due diligence. A technology partner with experience in working with both start-ups and large companies can successfully combine fast methods of digital project implementation with growing business needs.

2. Project management methods. In a dynamically changing environment (as we’re all experiencing now), our partner should be agile, i.e. proficient in implementations using modern methods, such as Agile, Scrum. This guarantees that the project will be delivered within a given budget and timeline.

3. The team’s knowledge of modern technologies. To quickly implement digital solutions from A to Z, our partner should have a complete team of specialists: developers, product strategists, product designers, project managers and quality assurance testers. Technology is key but its selection depends on the client’s specific needs. The success of a product or IT solution consists of combining all competencies “under one roof”.

4. Experience with international projects. This ensures the contractor combines their agile approach with good communication and an emphasis on system security. It also demonstrates the ability to work efficiently remotely which, especially nowadays, is a prerequisite for work continuity and can determine the success of a project.

A departure from the traditional model of long-lasting IT implementations made according to the so-called “specifications” towards rapid prototyping and implementing user-tested digital solutions is inevitable. Even more so in times when helping the client determine their needs and efficient workflows are more important than writing another line of code.

Share article on social media or email:

Smartlogic is Named as one of KMWorld’s AI50 – Companies Empowering Intelligent Knowledge Management


News Image

Smartlogic, The leader in Semantic AI solutions, has been named as one of KMWorld’s AI50 – Companies Empowering Intelligent Knowledge Management. This distinction is given to organizations with innovative knowledge management solutions that are incorporating AI and cognitive computing technologies into their offerings.

With more than 25 years of market coverage experience serving both technology professionals and executive management, KMWorld is the premier resource for actionable advice and real direction on solutions and strategies in knowledge, content, document and information management today. From advanced news and trends analysis to case studies and in-depth research, KMWorld guides more than 50,000 IT and business professionals at organizations across North America involved in the evaluation, recommendation, and purchase of enterprise technology products and services.

“We are excited to be recognized as part of KMWorld’s AI50. As the drive for digital transformation becomes imperative for organizations who want to compete and succeed in today’s digital economy, the need for intelligent technologies and services that enable speed, insight, and accuracy becomes key. That our product is recognized by KMWorld as one that provides the capabilities organizations need to thrive in an ever-changing economy is indeed high praise.” says Jeremy Bentley, CEO Smartlogic.

Semaphore, our Semantic AI platform, is designed for the world’s largest enterprises who demand scale and quality, it combines the power of Semantic AI with award-winning knowledge model management, precise classification and language services, and cutting-edge fact extraction capabilities.

Semaphore delivers more value to enterprise initiatives that require the aggressive use of data – structured and unstructured, internal and external to the organization. Organizations leverage Semaphore to capitalize on information across governance and compliance, provide excellent customer experiences, and gain valuable insights from previously unavailable information to drive new revenue streams, gain organizational efficiencies, and achieve cost savings.

About Smartlogic

Smartlogic’s Semaphore is a Semantic AI platform that enables organizations to reveal and extract knowledge from their digital data ecosystem to yield business insight. Semaphore enriches enterprise information with context and meaning, extracts critical facts and relationships, and harmonizes disparate enterprise information. Semaphore Integrates with content, data, and application systems; supports multiple data types – including graph – and incorporates AI and machine learning strategies to transform digital data into qualified actionable intelligence.

Semaphore is available on-premise; Software as a Service (SaaS); on-Demand and in hybrid mode. We support the information needs of the world’s largest enterprises to accelerate growth, prevent revenue leakage, minimize risk, govern enterprise information, and deliver value to their organization, customers, partners, and suppliers.

Share article on social media or email:

Nutrition Digital Health Startup Nutrimedy Partners with TechSpring at Baystate Health to Support Oncology Patients


As part of it’s expansion of their Digital Health R&D Sandbox Program, Massachusetts eHealth Institute (MeHI) has announced that it has awarded a grant to TechSpring, the Baystate Health Technology Innovation Center. This grant will enable them to work with Nutrimedy ,“…to access TechSpring’s product development acceleration services and work with experienced Innovation Managers to test and validate their products in a real healthcare environment.”

Nutrimedy’s mission is to improve health and reduce the epidemic burden of chronic disease by improving access to convenient, expert, personalized and affordable nutritional counseling. Through the grant, Nutrimedy, based in Brookline, will work with TechSpring’s Innovation Managers to complete the discovery, planning, and execution of a pilot project that will provide Nutrimedy’s patient-facing nutritional support platform to oncology patients at Baystate Health pre-surgery. Nutrimedy will work with TechSpring and Baystate Health to gather user feedback from the participating patients and clinicians and to assess the effectiveness in Nutrimedy’s platform in helping increase patients’ access to clinical nutrition care and to reach their pre-surgical nutritional goals.

“There is a high prevalence of malnutrition in cancer patients, with some studies showing that as many as 80% of patients have some degree of malnutrition. Access to clinical nutrition care through Nutrimedy will allow patients to connect with a dietitian remotely and be proactively managed prior to surgery,” said Karolina Starczak, CEO of Nutrimedy.

The funding for the Sandbox Program is part of Massachusetts’ “…efforts to boost the digital health ecosystem under the Massachusetts Digital Health Initiative.” This grant will allow Nutrimedy to access TechSpring’s unique innovation environment to more quickly test, validate, and advance their product. “The mutual benefit of working with Nutrimedy is that we get to learn together how to scale these types of digital tools,” said Jill McCormick, Director of Design and Innovation at TechSpring, based in Springfield, Mass.

Mallory Franklin, Chief Clinical Officer of Nutrimedy, spearheaded the effort to receive the Sandbox Grant. She says, “Cancer-related malnutrition is the cause of death in as many as 40% of cancer patients and providing clinical nutrition care through telehealth can remove barriers to access for patients. That’s why with the support of the Sandbox Program, we are thrilled to be working with Baystate Health and TechSpring to provide an innovative approach to connecting patients to the care they need through Nutrimedy’s digital health platform.”

About Nutrimedy:

Nutrimedy is a digital health company focused on the next generation of evidence- based clinical nutrition care to provide real-time at-point recommendations and decision making assistance to patients using a virtual model. Nutrimedy provides longitudinal support and guidance for over 50 conditions through built-in video appointments with registered dietitians, secure messaging, file sharing, educational content, customizable trackers and AI-enabled photo food logging. To find out more visit http://www.nutrimedy.com

About TechSpring, Baystate Health’s Technology Innovation Center:

TechSpring is a technology innovation organization that, with direct connection to Baystate Health, https://www.baystatehealth.org/, a large integrated health system, provides leading technology companies with access to real healthcare resources and a representative community to test, prove, and accelerate their innovative solutions. The TechSpring Insights program connects innovators directly to users and other sources critical to drive and validate product development and adoption and to go to market with a competitive advantage. Learn more about TechSpring goat https://www.techspringhealth.org/ and follow @TechSpringMA on Twitter.

About the Massachusetts eHealth Institute:

MeHI, or the Massachusetts eHealth Institute at the Massachusetts Technology Collaborative, is the Commonwealth’s entity for healthcare innovation, technology, and competitiveness, and partners with industry, government, and healthcare organizations to support the Massachusetts Digital Health Initiative on behalf of the Baker-Polito Administration. MeHI also helps Massachusetts healthcare providers harness the benefits of electronic health records and the Mass HIway, the statewide health information exchange. For more information, please visit https://mehi.masstech.org and follow @MassEHealth. Learn more about the Massachusetts Digital Health Initiative at http://www.massdigitalhealth.org.

Share article on social media or email:

Arcview Market Research and BDSA Agree the Declaration of Cannabis as an ‘Essential Service’ Amid COVID-19 Pandemic Is Historic Moment


DECLARATION OF CANNABIS AS AN ‘ESSENTIAL SERVICE’ AMID COVID-19 PANDEMIC IS HISTORIC MOMENT

DECLARATION OF CANNABIS AS AN ‘ESSENTIAL SERVICE’ AMID COVID-19 PANDEMIC IS HISTORIC MOMENT

The fundamental fact underlying the forecast of worldwide growth to $46.8 billion in 2025 is simple: even at $14.8 billion in 2019, legal spending represented just a sliver of global cannabis spending, including the illicit trade

Arcview Market Research and BDSA (formerly BDS Analytics) forecast worldwide legal cannabis industry revenue will grow another 38% to $20.4 billion in 2020. The eighth edition of the widely-cited “State of Legal Cannabis Markets” series also forecasts sales to reach $46.8 billion in 2025, growing at a 21.2% compound annual growth rate (CAGR) from 2019-2025.

Cannabis has been designated an “essential service” by state governments amid COVID-19 restrictions within cannabis-friendly U.S. states, demonstrating the dramatic change of status for cannabis over the last decade. Most notably, the designation enables government and industry to work together effectively towards a common goal of improving the economy and providing critical access to medical and wellness products. As quarantines lift, support from state officials looking to fill budget shortfalls from the recession could result in more legalization efforts.

“The shelter-in-place orders that began in mid-March could prompt cash-starved state governments to accelerate legalization in a bid for tax revenue,” said Troy Dayton, founder and Chief Strategy Officer of The Arcview Group. “Despite several states postponing planned 2020 legalization ballot measures due to COVID-19, the current forecast shows all Americans having access to medical cannabis by 2025.”

The global legal cannabis industry CAGR of 34.3% (between 2013 and 2019) can be mostly attributed to shifting views and baseline demand. Looking ahead, the worldwide market is expected to more than triple- from $14.8 billion in 2019 to $46.8 billion- in 2025. The top contributors to U.S. growth will include California, Florida, New York, Illinois, and New Jersey.

“The fundamental fact underlying the forecast of worldwide growth to $46.8 billion in 2025 is simple: even at $14.8 billion in 2019, legal spending represented just a sliver of global cannabis spending, including the illicit trade,” said Roy Bingham, Executive Chairman at BDSA.

Other key trends analyzed in the State of the Legal Cannabis Markets, Eighth Edition, include:


  • Several key features of the U.S. market that will support a CAGR of 18.2% to $33.9 billion in 2025.
  • The implications for companies and investors as publicly traded cannabis companies transition from “story stocks” to equities that trade on fundamental analysis and management execution.
  • Canada’s combined medical and adult-use spending nearly tripled from $582 million to $1.6 billion in 2019. Revenue is forecast to grow 73% to $2.8 billion in 2020 due to growing store counts in populous provinces, plus the late-2019 allowance of new product types.
  • Germany constitutes 22% of overseas sales with its medical-only program. With most countries limiting legalization to medical cannabis, the major driver of spending for the forecast period will be Mexico’s anticipated legalization of adult use (both medical and recreational). Mexico and Germany are on-track to account for 40% of 2025 international sales, excluding the U.S. and Canada.

Through seven annual editions, The State of Legal Cannabis Markets has been the definitive report on the worldwide legal cannabis industry. Since the fifth edition, the report has been produced by Arcview Market Research in partnership with BDSA, bringing BDSA’s unique retail-sales tracking and consumer studies to the forecasting of legal cannabis spending in over 50 US states and territories, ten Canadian provinces and territories and 40 countries.

Order the full report of Arcview Market Research’s The State of Legal Cannabis Markets 8th Edition to get the latest cannabis industry data and give your company a dealmaking edge as you navigate the ever evolving cannabis industry https://research.arcviewgroup.com/solcm8/.

About The Arcview Group

The Arcview Group blazed the trail for cannabis investments and is the largest and 1st vertically integrated firm servicing the industry. As a trusted global leader and nexus for investors, companies, entrepreneurs, money-managers and community, Arcview provides an expansive ecosystem that delivers a broad spectrum of programs and services to the industry. Arcview is synonymous with best-in-class. By providing the tools necessary and curating top-notch cannabis companies, Investor Members have had the playbook that has enabled them to invest hundreds of millions in more than 300 private cannabis startups. Furthermore, Arcview Market Research is the #1 source cited for market data, thought leadership and insights. In early 2020, Arcview Ventures was launched, as a member-managed fund that pools resources and strategic alliances together to make collective investment decisions. Arcview continues to expand novel programs, proprietary technology and platforms and international footprint. For more information, please visit https://arcviewgroup.com/

About BDSA

Headquartered in Boulder, CO, BDSA (formerly BDS Analytics) helps businesses improve revenues, reduce innovation risk and prioritize market expansion. The company provides a holistic understanding of the cannabinoid market by generating comprehensive, accurate and actionable insights across point-of-sale data, consumer research and global forecast models, available through the award-winning GreenEdge® data platform. To learn how you can utilize BDSA’s market research and insights, visit http://www.bdsa.com.

Share article on social media or email:

The 20 MSP Achieves HIPAA Compliance with Compliancy Group


HIPAA Compliance Verification Seal of Compliance

“We are all very excited to have completed the thorough process of becoming HIPAA compliant,” said Tim Conkle, CEO of The 20, “Our partnership with Compliancy Group will greatly benefit our MSP members and end clients.”

The 20 is pleased to announce that it has taken all necessary steps to prove its good faith effort to achieve compliance with the Health Insurance Portability and Accountability Act (HIPAA). Through the use of Compliancy Group’s proprietary HIPAA solution, The GuardTM The 20 can track their compliance program and has earned their Seal of ComplianceTM. The Seal of Compliance is issued to organizations that have implemented an effective HIPAA compliance program through the use of The Guard.

HIPAA is made up of a set of regulatory standards governing the security, privacy, and integrity of sensitive healthcare data called protected health information (PHI). PHI is any individually identifiable healthcare-related information. If vendors who service healthcare clients come into contact with PHI in any way, those vendors must be HIPAA compliant.

The 20 has completed Compliancy Group’s Implementation Program, adhering to the necessary regulatory standards outlined in the HIPAA Privacy Rule, Security Rule, Breach Notification Rule, Omnibus Rule, and HITECH. Compliancy Group has verified The 20’s good faith effort to achieve HIPAA compliance through The Guard.

“We are all very excited to have completed the thorough process of becoming HIPAA compliant,” said Tim Conkle, CEO of The 20, “Our partnership with Compliancy Group will greatly benefit our MSP members and end clients. We will ensure that both their business and IT practices are adhering to HIPAA regulations and standards.”

Clients and patients are becoming more aware of HIPAA compliance requirements and how the regulation protects their personal information. Forward-thinking providers like The 20 choose the Seal of Compliance to differentiate their services.

About The 20:

The 20 is an exclusive business development group for Managed Service Providers (MSP) aimed at dominating and revolutionizing the IT industry with its standardized all-in-one approach. The 20’s robust RMM, PSA, and documentation platform ensures superior service for its MSPs’ clients utilizing their completely US-based Help Desk and Network Operations Center. Extending beyond world-class tools and processes, The 20 touts a proven sales model, a community of industry-leaders, and ultimate scalability. For more information, visit https://www.the20.com.

Follow The 20: Twitter, LinkedIn and Facebook

About Compliancy Group:

HIPAA should be simple. That’s why Compliancy Group is the only HIPAA software with expert Compliance CoachesTM holding your hand to simplify compliance. Built by auditors, Compliancy Group gives you confidence in your compliance plan to reduce risk, increase patient loyalty, and profitability of your organization. Visit https://www.compliancy-group.com or call 855.854.4722 to learn how simple compliance can be.

Verify our Seal of Compliance!

Share article on social media or email:



US BioTek Laboratories Launches COVID-19 Testing Services


US BioTek Laboratories, a CLIA (Clinical Laboratory Improvement Amendments) accredited laboratory, announces that it has expanded its capabilities to include coronavirus testing. Best known as a provider of immunology profiles used to identify food and airborne allergies and sensitivities, US BioTek performs FDA EUA authorized diagnostic (RT-PCR) and antibody tests for COVID-19 at its Shoreline, WA facility. Available for use by licensed healthcare providers, the addition of COVID-19 testing comes at a time when many US labs are reaching or near capacity, resulting in long wait times for patient results. US BioTek can serve as an additional COVID-19 testing resource anywhere in the country and help healthcare providers accelerate the process for their patients, with turnaround times of typically 24-48 hours including shipping.

“As the magnitude of COVID-19 became apparent, we recognized that we had a unique capability to provide much needed testing,” said Jack Frausing, CEO of US BioTek Laboratories. “We have a modern, state-of-the-art lab and trained staff already in place, so adding this much-needed service was an easy decision. We are pleased to be able to do our part in the fight against the virus.”

US BioTek’s COVID-19 Diagnostic Test has received FDA EUA authorization (https://www.fda.gov/media/137922/download) and is performed on a Thermo Fisher system using real-time reverse polymerase chain reaction (RT-PCR) technology to detect the presence of the SARS-CoV-2 virus in a patient, the current standard for identifying infected individuals. The test is performed using a sample collected from a patient by nasopharyngeal, oropharyngeal, nasal mid-turbinate, or anterior nasal swab. Additional collection methods are currently under review and will be supported by US BioTek once approved for use by the FDA.

US BioTek also offers a serological test to detect antibodies to the virus. This test has also received FDA EUA (https://www.fda.gov/media/138071/download) and is performed on a high sensitivity electro chemiluminescent platform developed by Roche, and the test may help to identify prior exposure to the SARS-CoV-2 virus. It can also be used to confirm a COVID-19 test result performed on a PCR system, particularly when a false-negative result is suspected due to inadequate sample collection.

More information on both tests can be found on US BioTek Laboratories’ website at https://www.usbiotek.com/covid-19-tests.

About US BioTek Laboratories

US BioTek Laboratories, Inc. is a Clinical Laboratory Improvement Amendments (CLIA) accredited testing facility headquartered north of Seattle in Shoreline, Washington. With over 30 years’ experience in enzyme-linked immunosorbent assay technology, it employs the latest laboratory science, advanced automation technology, and a dedicated research team to ensure the accuracy and reproducibility of each test it performs. More information is available at http://www.usbiotek.com.

US BioTek Laboratories has received approval from the Washington State Department of Health to perform COVID-19 RT-PCR and antibody tests (https://www.usbiotek.com/hubfs/Licenses%20and%20Certificates/US%20BioTek%20COVID-19%20WA%20DOH%20Approval.pdf). As stated in Section IV.B of the FDA’s Policy for Coronavirus Disease-2019 Tests, a State or territory choosing to authorize laboratories within that State or territory to develop and perform a test for COVID-19 would do so under authority of its own State law, and under a process that it establishes. As noted in the guidance, FDA does not intend to object to the use of such tests for specimen testing where the notification of SARS-CoV-2 test validation is not submitted to FDA and the laboratory does not submit an EUA request to FDA, and where instead the State or territory takes responsibility for COVID-19 testing by laboratories in its State/territory during the COVID-19 outbreak. The Washington State Department of Health has notified FDA that they choose to use this flexibility to expedite COVID-19 testing.

Share article on social media or email:

County Line Chiropractic is Proud to Open a New Location in East Fort Lauderdale


County Line Chiropractic opens 6th new location in East Fort Lauderdale

County Line Chiropractic has opened a new location in East Fort Lauderdale.

Car accident victims have a new place to turn when seeking treatment for ongoing aches and pains, now that County Line Chiropractic has opened a new location in East Fort Lauderdale.

County Line Chiropractic specializes in helping car accident victims deal with their injuries in a holistic manner that doesn’t involve pain medication or invasive treatments and procedures. Instead, they believe that a customized treatment plan should dive into the root cause of the pain. Now with six convenient locations, it is easier than ever for patients with new or chronic pain to seek treatment.

The new East Fort Lauderdale location at 926 East Cypress Creek Road in Fort Lauderdale, Florida, offers several versatile treatment options and diagnostic tests. Run by Dr. Laura Hochstein, formerly of the Miami Gardens location, patients can receive ultrasound therapy, hands-on chiropractic treatments, and physical rehabilitation in a private treatment room. Patients can schedule an appointment over the phone or online, and walk-ins are also welcome. Transportation for auto accident victims will also be offered at the East Fort Lauderdale location.

Dr. Laura Hochstein is a Broward County Native who has a Bachelor of Science degree in Biology, as well as a Doctorate in Chiropractic Medicine. She was inspired to become a chiropractor after growing up watching her father, Dr. Robert Hochstein, help patients pinpoint the underlying causes of their pain. Now, she continues the legacy from the new County Line Chiropractic office in East Fort Lauderdale.

For more information about the new East Fort Lauderdale location, visit the County Line Chiropractic website.

More About County Line Chiropractic

At County Line Chiropractic, our mission is to help our patients find pain relief through natural recovery. Our experienced chiropractors are determined to find the source of your injury and design a customized care plan to heal your body effectively and naturally to reduce long-term or chronic pain. We have been serving the residents of Miami Gardens, North Miami Beach, Plantation, Pembroke Pines, and Lauderhill in Florida since 1986 and are ready to help you.

We offer chiropractic care to anyone suffering from chronic pain or muscle aches and pains, as well as victims of work or auto injuries. Whatever your pain stems from, we will help find the cause and offer relief. Our chiropractors in the Broward and Miami-Dade counties help develop customized, non-invasive plans for long-term chiropractic care. For more information, please visit the County Line Chiropractic website (http://www.countylinechiro.com) or call 800-811-1231.

Share article on social media or email: